{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:26:26Z","timestamp":1789453586439,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T00:00:00Z","timestamp":1452297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003132","name":"Agentschap voor Innovatie door Wetenschap en Technologie (BE)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek (BE)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s11096-015-0242-9","type":"journal-article","created":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T01:40:40Z","timestamp":1452303640000},"page":"310-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium"],"prefix":"10.1007","volume":"38","author":[{"given":"Eline","family":"Vandael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Vandenberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Foulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,9]]},"reference":[{"key":"242_CR1","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.4103\/0976-500X.120957","volume":"4","author":"J Sultana","year":"2013","unstructured":"Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4:S73\u20137.","journal-title":"J Pharmacol Pharmacother"},{"key":"242_CR2","doi-asserted-by":"crossref","first-page":"e4439","DOI":"10.1371\/journal.pone.0004439","volume":"4","author":"EC Davies","year":"2009","unstructured":"Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4:e4439.","journal-title":"PLoS One"},{"key":"242_CR3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1365-2125.2006.02698.x","volume":"63","author":"RL Howard","year":"2007","unstructured":"Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63:136\u201347.","journal-title":"Br J Clin Pharmacol"},{"key":"242_CR4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2125.2003.01875.x","volume":"57","author":"PA Routledge","year":"2004","unstructured":"Routledge PA, O\u2019Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57:121\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"242_CR5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013\u201322.","journal-title":"N Engl J Med"},{"key":"242_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","volume":"54","author":"SR Beach","year":"2013","unstructured":"Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54:1\u201313.","journal-title":"Psychosomatics"},{"key":"242_CR7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","volume":"55","author":"BJ Drew","year":"2010","unstructured":"Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:934\u201347.","journal-title":"J Am Coll Cardiol"},{"key":"242_CR8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/CCM.0b013e318232db4a","volume":"40","author":"D Pickham","year":"2012","unstructured":"Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in practice (QTIP) study. Crit Care Med. 2012;40:394\u20139.","journal-title":"Crit Care Med"},{"key":"242_CR9","unstructured":"Arizona Center for Education and Research on Therapeutics (AZCERT). QT-drug lists by risk groups (online), 2014. http:\/\/www.crediblemeds.org . Accessed 31 Aug 2014."},{"key":"242_CR10","first-page":"552","volume":"28","author":"D Ames","year":"2002","unstructured":"Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, et al. Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the cardiac safety in schizophrenia group. Encephale. 2002;28:552\u201362.","journal-title":"Encephale"},{"key":"242_CR11","unstructured":"Royal College of Psychiatrists, Consensus statement on high-dose antipsychotic medication, London, 2005."},{"key":"242_CR12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","volume":"59","author":"A Breier","year":"2002","unstructured":"Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"242_CR13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","volume":"24","author":"EP Harrigan","year":"2004","unstructured":"Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"242_CR14","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/jhm.691","volume":"5","author":"C Meyer-Massetti","year":"2010","unstructured":"Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5:E8\u201316.","journal-title":"J Hosp Med"},{"key":"242_CR15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1592\/phco.30.2.127","volume":"30","author":"JJ Miceli","year":"2010","unstructured":"Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano R, O\u2019Gorman C, Harrigan RH. Effects of oral Ziprasidone and oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder. Pharmacotherapy. 2010;30:127\u201335.","journal-title":"Pharmacotherapy"},{"key":"242_CR16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clinthera.2010.03.003","volume":"32","author":"JJ Miceli","year":"2010","unstructured":"Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano RJ, O\u2019Gorman C, Harrigan RH. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther. 2010;32:472\u201391.","journal-title":"Clin Ther"},{"key":"242_CR17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pnpbp.2010.01.008","volume":"34","author":"Y Ozeki","year":"2010","unstructured":"Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:401\u20135.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"242_CR18","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","volume":"355","author":"JG Reilly","year":"2000","unstructured":"Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048\u201352.","journal-title":"Lancet"},{"key":"242_CR19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/11318880-000000000-00000","volume":"26","author":"WV Vieweg","year":"2009","unstructured":"Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging. 2009;26:997\u20131012.","journal-title":"Drugs Aging"},{"key":"242_CR20","unstructured":"FDA alert: Information for Healthcare Professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate), 9\/2007. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm085203.htm . Accessed 16 Jan 2015."},{"key":"242_CR21","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: ATC\/DDD Index (online), 2014. http:\/\/www.whocc.no\/atc_ddd_index . Accessed 31 Aug 2014."},{"key":"242_CR22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.mayocp.2013.01.013","volume":"88","author":"KH Haugaa","year":"2013","unstructured":"Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc. 2013;88:315\u201325.","journal-title":"Mayo Clin Proc"},{"key":"242_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1056-8719(03)00008-X","volume":"48","author":"P Davey","year":"2002","unstructured":"Davey P. How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods. 2002;48:3\u20139.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"242_CR24","unstructured":"U.S.Department of Health and Human Services. Guidance for Industry: E14 Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005."},{"key":"242_CR25","doi-asserted-by":"crossref","first-page":"e23728","DOI":"10.1371\/journal.pone.0023728","volume":"6","author":"MT Blom","year":"2011","unstructured":"Blom MT, Bardai A, van Munster BC, Nieuwland MI, de Jong H, van Hoeijen DA, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS One. 2011;6:e23728.","journal-title":"PLoS One"},{"key":"242_CR26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/jgs.12049","volume":"61","author":"D Cheung","year":"2013","unstructured":"Cheung D, Wolfe B, Wald H, Cumbler E. Unsafe use of intravenous haloperidol: evaluation of recommendation-concordant care in hospitalized elderly adults. J Am Geriatr Soc. 2013;61:160\u20131.","journal-title":"J Am Geriatr Soc"},{"key":"242_CR27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/11599960-000000000-00000","volume":"35","author":"AJ Muzyk","year":"2012","unstructured":"Muzyk AJ, Rayfield A, Revollo JY, Heinz H, Gagliardi JP. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Drug Saf. 2012;35:547\u201353.","journal-title":"Drug Saf"},{"key":"242_CR28","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM199711273372202","volume":"337","author":"J McAnulty","year":"1997","unstructured":"McAnulty J, Halperin B, Kron J, Larsen G, Raitt M, Swenson R, et al. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576\u201383.","journal-title":"N Engl J Med"},{"key":"242_CR29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJMoa012407","volume":"347","author":"ES Soteriades","year":"2002","unstructured":"Soteriades ES, Evans JC, Larson MG, Chen MH, Chen L, Benjamin EJ, et al. Incidence and prognosis of syncope. N Engl J Med. 2002;347:878\u201385.","journal-title":"N Engl J Med"},{"key":"242_CR30","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.0000121328.12536.07","volume":"109","author":"DJ Wilber","year":"2004","unstructured":"Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109:1082\u20134.","journal-title":"Circulation"},{"key":"242_CR31","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/eurheartj\/ehu100","volume":"35","author":"S Fanoe","year":"2014","unstructured":"Fanoe S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J. 2014;35:1306\u201315.","journal-title":"Eur Heart J"},{"key":"242_CR32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1060028013512614","volume":"48","author":"CG Jardin","year":"2014","unstructured":"Jardin CG, Putney D, Michaud S. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents. Ann Pharmacother. 2014;48:196\u2013202.","journal-title":"Ann Pharmacother"},{"key":"242_CR33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s11096-014-9953-6","volume":"36","author":"E Vandael","year":"2014","unstructured":"Vandael E, Marynissen T, Reyntens J, Spriet I, Vandenberghe J, Willems R, et al. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium. Int J Clin Pharm. 2014;36:757\u201365.","journal-title":"Int J Clin Pharm"},{"key":"242_CR34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/pds.3792","volume":"24","author":"MJ Warnier","year":"2015","unstructured":"Warnier MJ, Rutten FH, Souverein PC, de Boer A, Hoes AW, De Bruin ML. Are ECG monitoring recommendations before prescription of QT prolonging drugs applied in daily practice? The example of haloperidol. Pharmacoepidemiol Drug Saf. 2015;24:701\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"242_CR35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/phar.1242","volume":"33","author":"JM Fongemie","year":"2013","unstructured":"Fongemie JM, Al-Qadheeb NS, Estes NA, Roberts RJ, Temtanakitpaisan Y, Ruthazer R, et al. Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation. Pharmacotherapy. 2013;33:589\u201397.","journal-title":"Pharmacotherapy"},{"key":"242_CR36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/hiv.12031","volume":"14","author":"N Patel","year":"2013","unstructured":"Patel N, Veve M, Kwon S, McNutt LA, Fish D, Miller CD. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation. HIV Med. 2013;14:463\u201371.","journal-title":"HIV Med"},{"key":"242_CR37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/BF03261969","volume":"35","author":"AJ Muzyk","year":"2012","unstructured":"Muzyk AJ, Rivelli SK, Jiang W, Heinz H, Rayfield A, Gagliardi JP. A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients. Drug Saf. 2012;35:725\u201331.","journal-title":"Drug Saf"},{"key":"242_CR38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1345\/aph.1K458","volume":"42","author":"TM Ng","year":"2008","unstructured":"Ng TM, Bell AM, Hong C, Hara JM, Touchette DR, Danskey KN, et al. Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: a pilot study. Ann Pharmacother. 2008;42:475\u201382.","journal-title":"Ann Pharmacother"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0242-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-015-0242-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0242-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T01:54:54Z","timestamp":1559354094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-015-0242-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,9]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s11096-015-0242-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,9]]}}}